To test whether IDO activity in cancer cells and TDLN participates synchronously in tumor progression, the current study analyzed the expression of IDO in cancer cells from primary tumor and lymph node metastases, in normal epithelium from adjacent non-cancerous tissues, and in immune cells from TDLN without tumor involvement in colon cancer. The gene discussed is IDO1; the disease is neoplasm.